
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$6.39
+US$0.02 · +0.31%
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
前收盤價
US$6.39
+US$0.02 · +0.31%
盤中時間採用ET。市場資料可能有所延遲。
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
日內區間
目前US$6.39
52週區間
目前US$6.39
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
47
合理估值
情緒
52
多空交錯
風險
68
高風險
動能
26
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
日內區間
目前US$6.39
52週區間
目前US$6.39
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2026會計年度 | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.29億 USD | 1.29億 USD | 1.28億 USD | 1.03億 USD | 1.11億 USD |
| 銷貨成本 | 8885.49萬 USD | 8856.9萬 USD | 8641.1萬 USD | 7528.4萬 USD | 7220.4萬 USD |
| 毛利 | 4060.97萬 USD | 4029.8萬 USD | 4185萬 USD | 2798.5萬 USD | 3906.6萬 USD |
| 研究與開發 | 850.3萬 USD | 825.8萬 USD | 857.5萬 USD | 873.6萬 USD | 783.9萬 USD |
| 銷售、一般及管理費用 | 3335.49萬 USD | 4404.6萬 USD | 4046.3萬 USD | 3896.9萬 USD | 3465.9萬 USD |
| 營業費用 | 4186.63萬 USD | 5754.3萬 USD | 5069.4萬 USD | 4978.1萬 USD | 5085.7萬 USD |
| 利息收入 | — | — | — | 6.8萬 USD | 8.1萬 USD |
| 利息支出 | 2669.83萬 USD | 2183.5萬 USD | 1809萬 USD | 1764.9萬 USD | 1555.1萬 USD |
| 折舊和攤銷 | 949.89萬 USD | 802.7萬 USD | 795.4萬 USD | 1317.7萬 USD | 1806.1萬 USD |
| 營業利益 | −125.66萬 USD | −1724.5萬 USD | −884.4萬 USD | −2179.6萬 USD | −1179.1萬 USD |
| 淨利 | −3079.03萬 USD | −3871.7萬 USD | 1201.3萬 USD | −9956.3萬 USD | −1.17億 USD |
公司資料更新於 2026年11月22日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動,並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM479.72萬0.01%715.37億 USD0.19%US$256.61-2.88%
Vanguard Morningstar Total Stock Market ETFVTI394.08萬0.00%6893億 USD0.03%US$340.02-3.52%
Vanguard Extended Market ETFVXF278.66萬0.00%302億 USD0.05%US$211.44-3.21%
iShares Russell 2000 Value ETFIWN175.05萬0.01%130.46億 USD0.24%US$198.84-2.08%
Vanguard Russell 2000 ETFVTWO106.25萬0.01%168億 USD0.06%US$103.76-2.76%
iShares Micro-Cap ETFIWC54.66萬0.05%10.88億 USD0.60%US$157.87-3.19%
Vanguard Russell 2000 Value ETFVTWV15.36萬0.01%13億 USD0.06%US$175.33-2.02%
iShares Russell 2000 Growth ETFIWO14.69萬0.00%127.32億 USD0.24%US$320.43-3.57%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Russell 2000 Value ETFIWN
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Vanguard Russell 2000 Value ETFVTWV
iShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。